RO7200220-hIgG2

Interleukin-6 (IL-6), an important pro-inflammatory cytokine released during infection or tissue damage, contributes to both innate and adaptive immune responses. Nevertheless, excessive production of IL-6 can result in the development of chronic inflammatory diseases such as rheumatoid arthritis and excessive inflammatory responses like cytokine storm. Some studies have discovered that IL-6 plays a crucial role in the development of uveitic macular edema. Specifically, uveitic macular edema is an eye disease caused by an abnormal immune response. It is typically associated with excessive immune response, and the level of IL-6 is often significantly elevated in this disease. Existing evidence suggests that IL-6 may cause fluid accumulation in the macular area by promoting inflammation and increasing vascular permeability, thus leading to macular edema. Therefore, inhibiting IL-6 could be a potential strategy for treating uveitic macular edema. RO7200220, an IL-6 monoclonal antibody developed by Roche, has potential application value in treating certain eye diseases.